Yoshinami, Tetsuhiro
Koizumi, Kei
Nagai, Shigenori E.
Toyama, Tatsuya
Iwata, Hiroji
Article History
Received: 22 October 2019
Accepted: 19 December 2019
First Online: 8 January 2020
Compliance with ethical standards
:
: Tetsuhiro Yoshinami received honoraria from Chugai, Kyowa Kirin, Novartis and Pfizer. Kei Koizumi received honoraria from Pfizer, Chugai, Eisai, Eli Lilly, Novartis, AstraZeneca, Merck Serono, Genomic Health, Allergan Japan, Kyowa Kirin, Daiichi Sankyo and Taiho. Shigenori E. Nagai received research funding from Chugai and Nippon Kayaku, and honoraria from Chugai, Novartis, Pfizer, Eli Lilly, Eisai and Taiho. Tatsuya Toyama received research funding from Chugai, Novartis, Eisai and AstraZeneca and honoraria from Chugai, Novartis, Eisai, AstraZeneca, Lilly, Kyowa Hakko Kirin, Taiho, Daiichi Sankyo, Nippon Kayaku, Pizer and Takeda. Hiroji Iwata received research funding from Chugai, Novartis, MSD and Lilly, honoraria from Chugai, AstraZeneca and Daiichi Sankyo, and serves as an advisory board to Daiichi Sankyo, Chugai, Lilly, Kyowa Hakko Kirin, Pfizer, Novartis and AstraZeneca.
: For this type of study, formal consent is not required.
: For this type of study, formal consent is not required.